Trial · NCT02121756
Adverse events42
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 42
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | gastrointestinal | Gastrointestinal disorders | ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24 | 13 | 21 | 49 |
| other | gastrointestinal | Gastrointestinal disorders | ARM B: Placebo for 12 Weeks From Baseline to Week 12 | 8 | 19 | 16 |
| other | gastrointestinal | Gastrointestinal disorders | ARM B: Dipyridamole for 12 Weeks From Week 12 to Week 24 | 5 | 19 | 18 |
| other | Neurologic | Nervous system disorders | ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24 | 13 | 21 | 28 |
| other | Neurologic | Nervous system disorders | ARM B: Placebo for 12 Weeks From Baseline to Week 12 | 5 | 19 | 6 |
| other | Neurologic | Nervous system disorders | ARM B: Dipyridamole for 12 Weeks From Week 12 to Week 24 | 6 | 19 | 11 |
| other | musculoskeletal | Musculoskeletal and connective tissue disorders | ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24 | 8 | 21 | 13 |
| other | musculoskeletal | Musculoskeletal and connective tissue disorders | ARM B: Placebo for 12 Weeks From Baseline to Week 12 | 2 | 19 | 3 |
| other | musculoskeletal | Musculoskeletal and connective tissue disorders | ARM B: Dipyridamole for 12 Weeks From Week 12 to Week 24 | 4 | 19 | 4 |
| other | cardiovascular | Cardiac disorders | ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24 | 6 | 21 | 12 |
| other | cardiovascular | Cardiac disorders | ARM B: Placebo for 12 Weeks From Baseline to Week 12 | 1 | 19 | 1 |
| other | cardiovascular | Cardiac disorders | ARM B: Dipyridamole for 12 Weeks From Week 12 to Week 24 | 3 | 19 | 3 |
| other | respiratory | Respiratory, thoracic and mediastinal disorders | ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24 | 5 | 21 | 7 |
| other | respiratory | Respiratory, thoracic and mediastinal disorders | ARM B: Placebo for 12 Weeks From Baseline to Week 12 | 1 | 19 | 1 |
| other | respiratory | Respiratory, thoracic and mediastinal disorders | ARM B: Dipyridamole for 12 Weeks From Week 12 to Week 24 | 5 | 19 | 5 |
| other | endocrine/metabolic | Endocrine disorders | ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24 | 3 | 21 | 4 |
| other | endocrine/metabolic | Endocrine disorders | ARM B: Placebo for 12 Weeks From Baseline to Week 12 | 0 | 19 | 0 |
| other | endocrine/metabolic | Endocrine disorders | ARM B: Dipyridamole for 12 Weeks From Week 12 to Week 24 | 1 | 19 | 1 |
| other | chemistries | Investigations | ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24 | 2 | 21 | 3 |
| other | chemistries | Investigations | ARM B: Placebo for 12 Weeks From Baseline to Week 12 | 2 | 19 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02121756/events